Cassava Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SAVA research report →
About the company
Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials.
- CEO
- Richard Jon Barry
- IPO
- 2000
- Employees
- 30
- HQ
- Austin, TX, US
Price Chart
- Market Cap
- $63.77M
- P/E
- -0.76
- P/S
- 0.00
- P/B
- 0.87
- EV/EBITDA
- 0.35
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -99.85%
- ROIC
- -120.10%
- Revenue
- $0 · 0.00%
- Net Income
- $-90,973,000 · -273.73%
- EPS
- $-1.88 · -254.72%
- Op Income
- $-95,390,000
- FCF YoY
- 71.95%
- 52W High
- $4.98
- 52W Low
- $1.15
- 50D MA
- $2.12
- 200D MA
- $2.51
- Beta
- -0.84
- Avg Volume
- 857.77K
Get TickerSpark's AI analysis on SAVA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 24, 25 | Anderson Robert Eugene Jr | buy | 8,600 |
| Nov 20, 25 | Barry Richard | buy | 150,000 |
| Nov 19, 25 | Barry Richard | buy | 73,385 |
| Oct 21, 25 | Bir Dawn Carter | other | 53,000 |
| Oct 21, 25 | Bir Dawn Carter | other | 0 |
| Sep 30, 25 | Cook Robert Christopher | buy | 13,725 |
| Sep 22, 25 | Barry Richard | buy | 7,172 |
| Sep 19, 25 | Barry Richard | buy | 46,908 |
| Sep 19, 25 | Barry Richard | buy | 400 |
| Sep 18, 25 | Barry Richard | buy | 185,233 |
Our SAVA coverage
Recent articles, reports, and earnings notes.
No research on SAVA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SAVA report →Similar companies
Peers in the same neighborhood.